TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04568694

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Lung Transplantation
Description: Transplants with a planned recipient anesthesia start time between 10:00 pm and 6:00 am will be allowed to move to a start time between 6:00 am and 8:00 am at the earliest. Donor lung(s) cross clamp time must occur between 5:00 pm and 4:00 am. Lungs that meet criteria will be transported in the usual fashion in a cooler of ice at 4oC. Upon arrival to NYULH, the lungs will be transferred to cold static preservation at 10oC within a specific incubator located in a NYULH OR (MYTEMP™65HC, Benchmark Scientific).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Lung Transplantation
Description: Reference Therapy
Study: NCT01528501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat (LBH589)
Study: NCT04464486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCH Intervention
Description: In addition to receiving usual care from their oncologist and staff, the SCH intervention group will report COVID-19 and cancer-related symptom presence and severity daily into the automated SCH system. Participants in the intervention receive automated self-management support messages for symptoms reported. In addition, COVID-19 symptoms and poorly controlled or worsening cancer symptoms will generate alerts. Based on preset thresholds, alerts automatically generate immediately from the patient's daily call data. The study nurse practitioners (NPs) monitor alerts. The NPs provide follow-up care using the guideline based SCH symptom clinical decision support system. The NPs log into the SCH Alert and Call Data website which displays all of the patients who have called that day and met an alert threshold. The NP calls the patient, delivers symptom management care by phone, and documents care in the patients' electronic health records.
Study: NCT03938259

Intervention type: DRUG
Intervention: Fentanyl
Description: identification of respiratory parameter changes following administration of fentanyl in children with and without OSA

Intervention type: DRUG
Intervention: Fentanyl
Description: identification of respiratory parameter changes following administration of fentanyl in children with and without OSA
Study: NCT02456415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: K-MET™ Bioresorbable Bone screw
Description: The biodegradable screw inserted into bone with an appropriate driver is slowly degraded and is completely degraded after completion of bone union and absorbed into the body. The screw is indicated for fixing damaged bone.
Study: NCT01639781

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol rich intervention
Description: Flavanol intervention drinks contain (400 mg flavanols) flavanol rich drink 2 x 400 mg 2 times a day over 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Flavanol free control
Description: Calorically, micro- and macronutrient matched control drink free of flavanols flavanol free drink 2 times a day over 2 weeks
Study: NCT05310019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy and Electroacupuncture
Description: TThe physiotherapy treatment (50min): warm compress with facial thermal blanket, respiratory muscle mobility training and cervical muscle relaxation, facial lymphatic drainage, start of myolymphokinetic exercises for the orbicularis, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma, release of intraoral adhesions, vacuum therapy at 60 mmHg, active exercises free of mandibular movements, maintenance of mandibular opening with wooden tongue depressors. The electroacupuncture treatment lasting another 30 min. Electroacupuncture treatment lasting another 30min. The repetition time of 1 sec; (F1-10 Hz, F2= 45 Hz; 10 mA). Facial acupuncture needles are disposable with 0.20 mm gauge and 10 mm length. Each needle will be inserted at the indicated points, totaling 10 needles and electrodes will be connected to each one. Electrical stimulation will be performed on the face points: E4, Jiachengjiang (extra point), E5, E6, bilaterally and point CV-24.
Study: NCT03710031

Intervention type: OTHER
Intervention: PNS Tracking
Description: Through blood and stool samples the study team will track the interplay among PNS as they relate to diminished QOL. Symptoms tracked include neurocognitive dysfunction, fatigue, anxiety, depression and pain, inflammation (cytokines and C-reactive protein), gut microbiota \[(GM) richness and diversity\] and diet (macronutrients: carbohydrates, fats and proteins).
Study: NCT00287495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 43-9006
Description: BAY 43-9006 200 mg once daily with dose escalation up to 400 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 43-9006
Description: BAY 43-9006 200 mg once daily with dose escalation up to 400 mg twice daily
Study: NCT03131583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Day-14\~Day16 qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Day1 and Day8 qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: Day3\~Day8 qd
Study: NCT02238353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelastine + fluticasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05310019

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: The physiotherapy treatment protocol will be divided into 6 meetings: warm compress with facial thermal blanket (5min), respiratory muscle mobility training and cervical muscle relaxation (5min) facial lymphatic drainage (10min), start of myolymphokinetic exercises for the orbicularis oris, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma (5 min), release of intraoral adhesions (5min) vacuum therapy at 60 mmHg (5min), active exercises free of mandibular movements (5 min), maintenance of mandibular opening with wooden tongue depressors (10min).
Study: NCT00730457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX125
Description: Single intramuscular dose
Study: NCT03422523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous drip
Study: NCT01347112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: varenicline 1.0 mg dose, twice daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sugar pill twice daily for 12 weeks
Study: NCT03422523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Intravenous drip/or Subcutaneous from cycle 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous drip/or Subcutaneous from cycle 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine 1000 mg
Description: intravenous drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg
Description: intravenous drip

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin 100 MG
Description: intravenous drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 100 MG
Description: intravenous drip
Study: NCT03133052

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: internet-based adaptive cognitive control training program
Description: The cognitive training will be an internet-based adaptive cognitive control training program, specific training paradigms include Flanker, 1-back, 2-back. To maintain task difficulty, the tasks will be grouped based on the task difficulty. Furthermore, each task will have various difficulty levels.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo program
Description: For the control group, a fixed, primary difficulty level program for all participants is set.
Study: NCT04190641

Intervention type: DEVICE
Group type: OTHER
Intervention: Ambu aScope 4 Cysto and aView Urologia
Description: Visualization of the urethra and the bladder
Study: NCT02124369

Intervention type: DRUG
Group type: OTHER
Intervention: Abraxane
Description: 125mg/m2, IV, on days 1,8 \& 15 of each 28 day cycle, up to 6 cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: 1000mg/m2, IV, on days 1,8 \& 15 of a 28 day cycle, up to 6 cycles.
Study: NCT00497094

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: carotid artery stenting
Description: Using retrograde transfemoral access an overview aortic angiogram is established. A stiff wire is then placed in the external carotid or distal common carotid artery to introduce a long hydrophilic sheath into the common carotid artery. The stenosis is then crossed with a Filter wire. For stent implantation Monorail Carotid Wallstents or the Monorail Nitinol Stent of Boston Scientific are used. Road map or overlay technique with a magnification of 20 to 28 inch is used to localize the stenosis during the procedure. Finally a control angiogram is performed to ensure correct placement of the stent. After successful completion of the procedure, the arterial access site is closed using a standard closure device.
Study: NCT02700061

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic occupational therapy
Description: Robotic Occupational Therapy three times a week for twelve weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induced Constraint Therapy - ICT
Description: Standard Occupational Therapy two times a week for ten weeks, followed by two whole weeks of Induced Constraint Therapy.
Study: NCT03762811

Intervention type: DEVICE
Group type: OTHER
Intervention: NanoFUSE® Bioactive Matrix
Description: NanoFUSE® is placed into bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure.
Study: NCT02798627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS2359
Description: NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pills identical in appearance to the NS2359 will be provided
Study: NCT02426346

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral weight control
Description: Prescription of diet \& physical activity and behavioral strategies for weight control

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight control
Description: Prescription of diet \& physical activity and behavioral strategies for weight control

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based physical activity
Description: Teens exercise for 60 minutes with their group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based incentives
Description: Adolescents earn reinforcements within group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent-based incentives
Description: Adolescents earn reinforcements from their parents (outside of group)
Study: NCT04684251

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coil embolisation of hemorrhoidal arteries.
Description: Coil embolisation of hemorrhoidal arteries as previously described.
Study: NCT00946101

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]
Description: 0.5 mL: (intranasal sprayer)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer
Study: NCT03660800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTAP101 Capsules
Description: Calcifediol Extended-Release Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTAP101 Capsules
Description: Calcifediol Extended-Release Capsules
Study: NCT02404935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI and cetuximab

Intervention type: DRUG
Group type: OTHER
Intervention: FOLFIRI and cetuximab
Study: NCT02084992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expanded technology disease management
Description: Tablet computers loaded with a web-based disease management program will be given to patients for the duration of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephonic disease management
Study: NCT01677897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Adding Metformin to Abiraterone in case of PSA-Progression
Study: NCT00520325

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous recombinant human mannose binding lectin
Description: Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous recombinant human mannose binding lectin
Description: Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
Study: NCT02873143

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04053660

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Mechanical non-surgical treatment were performed
Study: NCT01763697

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: taste acuity assessment
Description: Quantitative measurement of for tasting detection and recognition thresholds, magnitude of perception and hedonic response.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: taste acuity assessment
Description: Quantitative measurement of for tasting detection and recognition thresholds, magnitude of perception and hedonic response.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: taste acuity assessment
Description: Quantitative measurement of for tasting detection and recognition thresholds, magnitude of perception and hedonic response.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recorded meal

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recorded meal

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Recorded meal
Study: NCT04643210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: F2F MoB EI
Description: The MoB F2F EI will comprise a total of 12 educational F2F sessions. Each session will have a duration of 1.5 hours and the maximum number of participants in the groups will be 12 patients.~The intervention group will receive the MoB F2F EI on group or personal form according to the participant's choice. The implementation methodology of the MoB F2F EI will include videos and power point presentations, as well as interactive learning methods such as role-playing, empowerment exercises, live discussions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MoB DP
Description: This is a technology-based intervention, which regards access to a dfigital platform, the MoB DP. The structure of the Digital platform has been partially based on the preferences and needs of the participants (as described in the qualitative part of the study) and its goal is to create an ecosystem where users will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile. The Digital platform will be in the form of a dynamic website with user generated content as well as static information.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MoB DP
Description: This is a technology-based intervention, which regards access to a dfigital platform, the MoB DP. The structure of the Digital platform has been partially based on the preferences and needs of the participants (as described in the qualitative part of the study) and its goal is to create an ecosystem where users will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile. The Digital platform will be in the form of a dynamic website with user generated content as well as static information.
Study: NCT02671708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin（IDA）
Description: Idarubicin was administered at 15mg/m2/day on days -12 and -10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study: NCT00000817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride
Description: 75 mg oral tablet taken daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride placebo
Description: Oral placebo tablet taken daily

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Point acupuncture
Description: Standardized or alternate acupuncture procedure
Study: NCT03428984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: EXAPREL 266 mg in 20 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: EXAPREL 266 mg in 20 mL
Study: NCT00313014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Immediate-Release
Description: Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).
Study: NCT02254135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEA 2180 BR - rising dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01466712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium + formoterol/beclometasone
Description: Tiotropium 18 µg/dose once daily (handihaler device) + formoterol, fumarate 6µg + beclometasone, dipropionate 100µg / dose (Pressurised inhaler): 2 puffs bid, for one month.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: tiotropium + placebo
Description: Tiotropium 18 µg/dose once daily (handihaler device) + placebo (Pressurised inhaler): 2 puffs bid, for one month.
Study: NCT01703143

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser ablation
Description: Laser ablation of focal lesions in patients with medically refractory partial epilepsy.
Study: NCT03081117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin, intranasal
Description: Regular insulin administered by specialized, non-commercial intranasal drug delivery device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, intranasal
Description: Saline solution administered by specialized, non-commercial intranasal drug delivery device
Study: NCT04216056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Frailty intervention program
Description: There will be 2 sessions per week for 12 weeks. Each session includes 1 hour exercise (including 5-10 minute warm-up and cool-down routine, 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body, and 20-30 minutes aerobic exercises); and 1 hour game training using computer video games, board games and card games. Nutrition education will be given to the subjects based on their weight status. The 1st level of nutrition information (healthy eating tips for frailty prevention and management) will be given to all subjects on regular basis during the 12-week study period via short videos, text messages or Whatsapp reminders. On top of the 1st level nutrition information, 3 nutrition heath talks (1-1.5 hours per talk) about weight management will be given to those with BMI \>=25 kg/m2, and/or waist circumference \>=90 cm (male) or \>=80 cm (female) during the 12-week study period.
Study: NCT02181777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GRASP
Description: GRoup trAining for Social skills in Psychosis

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Treatment as usual
Study: NCT04280250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volitional Help-Sheet
Description: Self-help sheet in order to form implementation intentions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: Psychoeducational self-help sheet
Study: NCT02289586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: invasive ventilation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional bronchoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interventional bronchoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasive ventilation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sedation(dezocine and midazolam)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia(midazolam, fentanyl，rocuronium，propofol and Remifentanil）
Study: NCT00222612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced intensification
Description: Deletion of one 7 week treatment block containing dexamethasone, vincristine, doxorubicin, Peg-asparaginase, intrathecal methotrexate, cyclophosphamide, cytarabine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard childhood UK ALL protocol
Description: No additional treatment to standard protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensified treatment including Capizzi maintenance
Description: Augmented consolidation: vincristine, Peg-asparaginase. Capizzi maintenance: iv methotrexate and peg-asparaginase
Study: NCT02902458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual interview with a qualified psychologist
Description: Individual, recorded interview with a qualified psychologist to discuss any and all subjects related to the ICD implantation, or any other topics deemed relevant by the patient.
Study: NCT01801163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib x 2 weeks followed by Stereotactic Radiotherapy and then sorafenib until disease progression.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Sorafenib x 2 weeks followed by Stereotactic Radiotherapy then Sorafenib until disease progression.